Compare MCB & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | MGTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 909.1M |
| IPO Year | 2017 | 2018 |
| Metric | MCB | MGTX |
|---|---|---|
| Price | $93.29 | $10.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $98.67 | $24.57 |
| AVG Volume (30 Days) | 85.8K | ★ 723.3K |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 11.64 | ★ 33.02 |
| EPS | ★ 2.92 | N/A |
| Revenue | $11,053,000.00 | ★ $81,391,000.00 |
| Revenue This Year | $37.22 | $141.38 |
| Revenue Next Year | $14.75 | N/A |
| P/E Ratio | $32.84 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $64.55 | $6.30 |
| 52 Week High | $97.84 | $11.85 |
| Indicator | MCB | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 61.38 |
| Support Level | $86.38 | $8.84 |
| Resistance Level | $93.56 | $10.46 |
| Average True Range (ATR) | 2.52 | 0.58 |
| MACD | 0.31 | 0.07 |
| Stochastic Oscillator | 55.12 | 80.74 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.